Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

KCGI Formally Goes Activist on Osstem Implant

A Tender Offer of Osstem Implant by MBK & Unison Capital?

Detailing Maekyung Report on MBK's Tender Offer to Osstem Implant Shareholders at a 20% Premium

KOSDAQ150: Details of Osstem Implant Exclusion & Caregen Inclusion and Case Study of SillaJen

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Event-Driven

<ul>
<li>The case involving KCGI (a local corporate activist private equity fund) and Osstem Implant (048260 KS) is one of the more interesting situations rising in the Korea's M&amp;A/corporate activism markets. </li>
<li>Osstem Implant is the number one dental implant company in Korea/Asia and the fourth largest player in this segment globally. </li>
<li>We believe Osstem Implant could outperform the market in 2023 due to improving fundamentals, cheap valuations, and a potential M&amp;A fight between KCGI and Chairman Choi.</li>
</ul>


The case involving KCGI (a local corporate activist private equity fund) and Osstem Implant (048260 KS) is one of the more interesting situations rising in the Korea's M&amp;A/corporate activism markets. 
Osstem Implant is the number one dental implant company in Korea/Asia and the fourth largest player in this segment globally. 
We believe Osstem Implant could outperform the market in 2023 due to improving fundamentals, cheap valuations, and a potential M&amp;A fight between KCGI and Chairman Choi.


Osstem Implant: Potential M&A Fight Between KCGI And Founder Choi